World Journal of Urology

, Volume 33, Issue 12, pp 1993–1999 | Cite as

Controversial evidence for the use of HistoScanning™ in the detection of prostate cancer

  • Jonas Schiffmann
  • Lukas Manka
  • Katharina Boehm
  • Sami-Ramzi Leyh-Bannurah
  • Pierre I. Karakiewicz
  • Markus Graefen
  • Peter Hammerer
  • Georg Salomon
Original Article
First Online:
Received:
Accepted:

Abstract

Introduction

Given the growing body of literature since first description of HistoScanning™ in 2008, there is an unmet need for a contemporary review.

Evidence acquisition

Studies addressing HistoScanning™ in prostate cancer (PCa) were considered to be included in the current review. To identify eligible reports, we relied on a bibliographic search of PubMed database conducted in January 2015.

Evidence synthesis

Twelve original articles were available to be included in the current review. The existing evidence was reviewed according to the three following topics: prediction of final pathology at radical prostatectomy, prediction of disease stage and application at prostate biopsy.

Conclusions

High sensitivity and specificity for HistoScanning™ to predict cancer foci ≥0.5 ml at final pathology were achieved in the pilot study. These results were questioned, when HistoScanning™ derived tumor volume does not correlate with final pathology results. Additionally, HistoScanning™ was not able to provide reliable staging information according to neither extraprostatic extension, nor seminal vesicle invasion prior to radical prostatectomy. Controversy data also exist according to the use of HistoScanning™ at prostate biopsy. Specifically, most encouraging results were recorded in a small patient cohort. Conversely, HistoScanning™ achieved poor prediction of positive biopsies, when relying on larger studies. Finally, the combination of HistoScanning™ and conventional ultrasound achieved lower detection rates than systematic biopsy. Currently, evidence is at best weak and questions whether HistoScanning™ might improve the detection of PCa.

Keywords

Histoscanning Imaging Prostate cancer Ultrasound 
This is a preview of subscription content, log in to check access.

Notes

Conflict of interest

The authors declare that they have no conflict of interest according to the current manuscript.

Ethical standard

The current manuscript has no conflict with ethical standards set by the local ethics committee of the Medical Board Hamburg.

References

  1. 1.
    Heidenreich A, Abrahamsson PA, Artibani W, Catto J, Montorsi F, Van Poppel H, Wirth M, Mottet N (2013) Early detection of prostate cancer: European Association of Urology recommendation. Eur Urol 64(3):347–354. doi: 10.1016/j.eururo.2013.06.051 CrossRefPubMedGoogle Scholar
  2. 2.
    Carroll PR, Parsons JK, Andriole G, Bahnson RR, Barocas DA, Catalona WJ, Dahl DM, Davis JW, Epstein JI, Etzioni RB, Giri VN, Hemstreet GP III, Kawachi MH, Lange PH, Loughlin KR, Lowrance W, Maroni P, Mohler J, Morgan TM, Nadler RB, Poch M, Scales C, Shanefelt TM, Vickers AJ, Wake R, Shead DA, Ho M (2014) Prostate cancer early detection, version 1.2014. Featured updates to the NCCN Guidelines. J Natl Compr Canc Netw 12(9):1211–1219 quiz 1219PubMedGoogle Scholar
  3. 3.
    Salomon G, Schiffmann J (2014) Real-time elastography for the detection of prostate cancer. Curr Urol Rep 15(3):392. doi: 10.1007/s11934-013-0392-z CrossRefPubMedGoogle Scholar
  4. 4.
    Boehm K, Salomon G, Beyer B, Schiffmann J, Simonis K, Graefen M, Budaeus L (2014) Shear wave elastography for localization of prostate cancer lesions and assessment of elasticity thresholds: implications for targeted biopsies and active surveillance protocols. J Urol. doi: 10.1016/j.juro.2014.09.100 PubMedGoogle Scholar
  5. 5.
    Braeckman J, Autier P, Garbar C, Marichal MP, Soviany C, Nir R, Nir D, Michielsen D, Bleiberg H, Egevad L, Emberton M (2008) Computer-aided ultrasonography (HistoScanning): a novel technology for locating and characterizing prostate cancer. BJU Int 101(3):293–298. doi: 10.1111/j.1464-410X.2007.07232.x CrossRefPubMedGoogle Scholar
  6. 6.
    Valerio M, Donaldson I, Emberton M, Ehdaie B, Hadaschik BA, Marks LS, Mozer P, Rastinehad AR, Ahmed HU (2014) Detection of clinically significant prostate cancer using magnetic resonance imaging-ultrasound fusion targeted biopsy: a systematic review. Eur Urol. doi: 10.1016/j.eururo.2014.10.026 PubMedCentralGoogle Scholar
  7. 7.
    Loch T (2007) Computerized transrectal ultrasound (C-TRUS) of the prostate: detection of cancer in patients with multiple negative systematic random biopsies. World J Urol 25(4):375–380. doi: 10.1007/s00345-007-0181-8 CrossRefPubMedGoogle Scholar
  8. 8.
    US National Institutes of Health. http://www.clinicaltrials.gov
  9. 9.
    Braeckman J, Autier P, Soviany C, Nir R, Nir D, Michielsen D, Treurnicht K, Jarmulowicz M, Bleiberg H, Govindaraju S, Emberton M (2008) The accuracy of transrectal ultrasonography supplemented with computer-aided ultrasonography for detecting small prostate cancers. BJU Int 102(11):1560–1565. doi: 10.1111/j.1464-410X.2008.07878.x CrossRefPubMedGoogle Scholar
  10. 10.
    Simmons LA, Autier P, Zat’ura F, Braeckman J, Peltier A, Romic I, Stenzl A, Treurnicht K, Walker T, Nir D, Moore CM, Emberton M (2012) Detection, localisation and characterisation of prostate cancer by prostate HistoScanning™. BJU Int 110(1):28–35. doi: 10.1111/j.1464-410X.2011.10734.x CrossRefPubMedGoogle Scholar
  11. 11.
    Javed SCE, Beveridge S, Bott S, Eden C, Langley S (2013) Does prostate Histoscanning™ accurately identify prostate cancer, measure tumour volume and assess pathological stage prior to radical prostatectomy? J Clin Urol. doi: 10.1177/2051415813489682 Google Scholar
  12. 12.
    Macek P, Barret E, Sanchez-Salas R, Galiano M, Rozet F, Ahallal Y, Gaya JM, Durant M, Mascle L, Giedelman C, Lunelli L, Validire P, Nesvadba M, Cathelineau X (2013) Prostate Histoscanning in clinically localized biopsy proven prostate cancer: an accuracy study. J Endourol. doi: 10.1089/end.2013.0419 PubMedGoogle Scholar
  13. 13.
    Schiffmann J, Fischer J, Tennstedt P, Beyer B, Bohm K, Michl U, Graefen M, Salomon G (2013) Comparison of prostate cancer volume measured by HistoScanning and final histopathological results. World J Urol. doi: 10.1007/s00345-013-1211-3 PubMedGoogle Scholar
  14. 14.
    D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280(11):969–974CrossRefPubMedGoogle Scholar
  15. 15.
    Salomon G, Spethmann J, Beckmann A, Autier P, Moore C, Durner L, Sandmann M, Haese A, Schlomm T, Michl U, Heinzer H, Graefen M, Steuber T (2013) Accuracy of HistoScanning for the prediction of a negative surgical margin in patients undergoing radical prostatectomy. BJU Int 111(1):60–66. doi: 10.1111/j.1464-410X.2012.11396.x CrossRefPubMedGoogle Scholar
  16. 16.
    Schiffmann J, Beyer B, Fischer J, Tennstedt P, Boehm K, Michl U, Graefen M, Salomon G (2014) Histoscanning has low sensitivity and specificity for seminal vesicle invasion. Urology 84(5):1168–1171. doi: 10.1016/j.urology.2014.06.050 CrossRefPubMedGoogle Scholar
  17. 17.
    Schlomm T, Tennstedt P, Huxhold C, Steuber T, Salomon G, Michl U, Heinzer H, Hansen J, Budaus L, Steurer S, Wittmer C, Minner S, Haese A, Sauter G, Graefen M, Huland H (2012) Neurovascular structure-adjacent frozen-section examination (NeuroSAFE) increases nerve-sparing frequency and reduces positive surgical margins in open and robot-assisted laparoscopic radical prostatectomy: experience after 11,069 consecutive patients. Eur Urol 62(2):333–340. doi: 10.1016/j.eururo.2012.04.057 CrossRefPubMedGoogle Scholar
  18. 18.
    Nunez-Mora C, Garcia-Mediero JM, Patino P, Orellana C, Garrido A, Rojo A, Rendon D (2013) Utility of Histoscanning prior to prostate biopsy for the diagnosis of prostate adenocarcinoma. Actas Urol Esp. doi: 10.1016/j.acuro.2013.01.003 PubMedGoogle Scholar
  19. 19.
    Javed S, Chadwick E, Edwards AA, Beveridge S, Laing R, Bott S, Eden C, Langley S (2013) Does HistoScanning play a role in detecting prostate cancer in routine clinical practice? Results from three independent studies. BJU Int. doi: 10.1111/bju.12568 PubMedGoogle Scholar
  20. 20.
    Schiffmann J, Tennstedt P, Fischer J, Tian Z, Beyer B, Boehm K, Sun M, Gandaglia G, Michl U, Graefen M, Salomon G (2014) Does HistoScanning predict positive results in prostate biopsy? A retrospective analysis of 1,188 sextants of the prostate. World J Urol 32(4):925–930. doi: 10.1007/s00345-014-1330-5 CrossRefPubMedGoogle Scholar
  21. 21.
    Sivaraman A, Sanchez-Salas R, Barret E, Macek P, Validire P, Galiano M, Rozet F, Cathelineau X (2014) Prostate histoscanning true targeting guided prostate biopsy: initial clinical experience. World J Urol. doi: 10.1007/s00345-014-1434-y PubMedGoogle Scholar
  22. 22.
    Schiffmann J, Connan J, Salomon G, Boehm K, Beyer B, Schlomm T, Tennstedt P, Sauter G, Karakiewicz PI, Graefen M, Huland H (2015) Tumor volume in insignificant prostate cancer: increasing threshold gains increasing risk. Prostate 75(1):45–49. doi: 10.1002/pros.22889 CrossRefPubMedGoogle Scholar
  23. 23.
    Ploussard G, Epstein JI, Montironi R, Carroll PR, Wirth M, Grimm MO, Bjartell AS, Montorsi F, Freedland SJ, Erbersdobler A, van der Kwast TH (2011) The contemporary concept of significant versus insignificant prostate cancer. Eur Urol 60(2):291–303. doi: 10.1016/j.eururo.2011.05.006 CrossRefPubMedGoogle Scholar
  24. 24.
    Wirth M, Weißbach L, Ackermann R, Alberti W, Albrecht C, Göckel-Beining B, Fröhner M, Hinkelbein W, Miller K, Rübben H (2011) Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms. AWMF, DüsseldorfGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  • Jonas Schiffmann
    • 1
  • Lukas Manka
    • 1
  • Katharina Boehm
    • 2
    • 3
  • Sami-Ramzi Leyh-Bannurah
    • 2
    • 4
  • Pierre I. Karakiewicz
    • 3
    • 5
  • Markus Graefen
    • 2
  • Peter Hammerer
    • 1
  • Georg Salomon
    • 2
    • 6
  1. 1.Department of UrologyAcademic Hospital BraunschweigBrunswickGermany
  2. 2.Martini-Clinic Prostate Cancer CenterUniversity Medical Center Hamburg-EppendorfHamburgGermany
  3. 3.Cancer Prognostics and Health Outcomes UnitUniversity of Montreal Health CenterMontrealCanada
  4. 4.Department of UrologyMedical University Center Hamburg-EppendorfHamburgGermany
  5. 5.Department of UrologyUniversity of Montreal Health CenterMontrealCanada
  6. 6.Martini-Clinic DiagnosticUniversity Medical Center Hamburg-EppendorfHamburgGermany

Personalised recommendations